ArticleAntimicrobial agents and chemotherapy2014
Echinocandin failure case due to a previously unreported FKS1 mutation in Candida krusei.
Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Genomic Insights ofOpen forum infectious diseases · 2026Review
- A Candidozyma (Candida) auris-Optimized Episomal Plasmid-Induced Cas9-Editing System Reveals the Direct Impact of the S639F-Encoding FKS1 Mutation.The Journal of infectious diseases · 2025Article
- Prevalence of Antifungal Resistance, Genetic Basis of Acquired Azole and Echinocandin Resistance, and Genotyping of Candida krusei Recovered from an International Collection.Antimicrobial agents and chemotherapy · 2022Article
- Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis.Frontiers in cellular and infection microbiology · 2021Review
- RezafunginAntimicrobial agents and chemotherapy · 2020Article
- Antifungal Activity and Mode of Action of Miltefosine Against Clinical Isolates ofFrontiers in microbiology · 2020Article
- EUCAST Reference Testing of Rezafungin Susceptibility and Impact of Choice of Plastic Plates.Antimicrobial agents and chemotherapy · 2019Article
- Population genomics shows no distinction between pathogenic Candida krusei and environmental Pichia kudriavzevii: One species, four names.PLoS pathogens · 2018Article
- Development of Echinocandin Resistance in Candida tropicalis following Short-Term Exposure to Caspofungin for Empiric Therapy.Antimicrobial agents and chemotherapy · 2018Article
- Genetic Differentiation, Diversity, and Drug Susceptibility ofFrontiers in microbiology · 2018Article
- Candidemia in a major regional tertiary referral hospital - epidemiology, practice patterns and outcomes.Antimicrobial resistance and infection control · 2017Article
- Echinocandin Resistance in Candida Species: a Review of Recent Developments.Current infectious disease reports · 2016Review
- Clinical perspectives on echinocandin resistance among Candida species.Current opinion in infectious diseases · 2015Review
- Rapid development of Candida krusei echinocandin resistance during caspofungin therapy.Antimicrobial agents and chemotherapy · 2015Article
- Implication of Candida parapsilosis FKS1 and FKS2 mutations in reduced echinocandin susceptibility.Antimicrobial agents and chemotherapy · 2015Article
- Echinocandin resistance: an emerging clinical problem?Current opinion in infectious diseases · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Echinocandins are the preferred therapy for invasive infections due to Candida krusei. We present here a case of clinical failure involving C. krusei with a characteristic FKS1 hot spot mutation not previously reported in C. krusei that was isolated after 14 days of treatment. Anidulafungin MICs were elevated by ≥ 5 dilution steps above the clinical breakpoint but by only 1 step for a Candida albicans isolate harboring the corresponding mutation, suggesting a notable species-specific difference in the MIC increase conferred by this mutation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.